Unveiling Analyst Ratings on Viridian Therapeutics (NASDAQ:VRDN)
Tuesday, 10 September 2024, 13:00
Understanding Analyst Ratings on Viridian Therapeutics (NASDAQ:VRDN)
Critical insights from Viridian Therapeutics analyst ratings reveal essential price targets. The average target is $34.0, highlighting significant growth potential. Analysts provide a high estimate of $56.00 and a low estimate of $27.00, showcasing diverse market opinions.
Price Targets Breakdown
- Average Target: $34.0
- High Estimate: $56.00
- Low Estimate: $27.00
Analysts' ratings are vital for investors considering Viridian Therapeutics, as they present a dynamic outlook on the company's performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.